Dr. Nissen Recaps PCSK9 News from ACC (Video)
FOURIER was the big news out of ACC, but other PCSK9 inhibitor trials mattered as well, including its EBBINGHAUS substudy and the SPIRE and ORION-1 trials. Dr. Steven Nissen outlines the takeaways.
If you couldn’t make it to the recent American College of Cardiology meeting to hear the big PCSK9 inhibitor trial presentations in person, we’ve got the next best thing: An expert’s take on the major PCSK9 study reports from the meeting.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In this three-minute video, Cleveland Clinic Cardiovascular Medicine Chair Steven Nissen, MD, sums up results and implications of four trials of importance presented at the meeting: